Clinical Trial Update: 36 vs 48 Wks Peg-Intron Plus Ribavirin for HCV Patients Without Rapid Virologic Response But Without HCV RNA at wk 8 [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial update comparing 36 weeks versus 48 weeks of PegIntron plus Ribavirin in hepatitis C patients who did not have a rapid virologic respon…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• PegIntron (pegylated interferon alfa-2b)
• Ribavirin (ribavirin)

Snippet

Sponsor: Chang Gung Memorial Hospital | Conditions: Hepatitis C Infection | Phase 4 | Status: UNKNOWN